Nature Search

Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial

In a multicenter, randomized trial of patients with atrial fibrillation and a low risk of thromboembolic events, treatment with the anticoagulant rivaroxaban showed no benefit in reducing cognitive decline, stroke or transient ischemic attack when compared to placebo.

Léna Rivard
Paul Khairy
William Liang
ResearchOpen Access07 Jan 2026
Nature Medicine

Volume: 32, P: 297-305
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

In the randomized phase 3 AMPLITUDE trial, patients with HRR-deficient mCSPC experienced longer progression-free survival when they were treated with niraparib and AAP compared to placebo and AAP.

Gerhardt Attard
Neeraj Agarwal
Dana E. Rathkopf
ResearchOpen Access07 Oct 2025
Nature Medicine

Volume: 31, P: 4109-4118
Pembrolizumab and chemotherapy in high-risk, early-stage, ER⁺/HER2⁻ breast cancer: a randomized phase 3 trial

In this prespecified interim analysis of the KEYNOTE-756 phase 3 trial, pembrolizumab and chemotherapy treatment of patients with high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor-negative breast cancer improved the pathological complete response rate compared with chemotherapy alone.

Fatima Cardoso
Joyce O’Shaughnessy
Aditya Bardia
ResearchOpen Access21 Jan 2025
Nature Medicine

Volume: 31, P: 442-448
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Results from EMPOWER-Lung 3 demonstrate increased overall survival with cemiplimab plus platinum-doublet chemotherapy compared to cemiplimab as first-line treatment in patients with advanced non-small cell lung cancer, irrespective of PD-L1 expression.

Miranda Gogishvili
Tamar Melkadze
Petra Rietschel
ResearchOpen Access25 Aug 2022
Nature Medicine

Volume: 28, P: 2374-2380
Electrical semiconduction modulated by light in a cobalt and naphthalene diimide metal-organic framework

Photoactive and semiconducting metal-organic frameworks are desirable for electrical and photoelectrical devices, but remain rare. Here Demets and co-workers design a naphthalene diimide and cobalt based MOF with anisotropic electrical semiconductivity and a high responsivity of 2.5 × 10⁵ A W⁻¹.

Evandro Castaldelli
K. D. G. Imalka Jayawardena
Grégoire Jean-François Demets
ResearchOpen Access15 Dec 2017
Nature Communications

Volume: 8, P: 1-8
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Preclinical studies have shown that blockade of the CD73-adenosinergic pathway could improve anti-tumor immunity and response to other immune checkpoint inhibitors. Here the authors report the results of a randomized phase II trial of first-line durvalumab, paclitaxel and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced triple-negative breast cancer.

Laurence Buisseret
Delphine Loirat
Martine Piccart-Gebhart
ResearchOpen Access02 Nov 2023
Nature Communications

Volume: 14, P: 1-15
Compression of visual space before saccades

John Ross
M. Concetta Morrone
David C. Burr
Research10 Apr 1997
Nature

Volume: 386, P: 598-601
Born again babies

DAVID JONES
News & Views20 Feb 1992
Nature

Volume: 355, P: 682
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

A prespecified analysis of the DELIVER clinical trial shows that the sodium/glucose cotransporter 2 inhibitor dapagliflozin benefits patients categorized as having heart failure with improved ejection fraction, a class of patients at high risk of cardiac events but for which limited treatment data are available.

Orly Vardeny
James C. Fang
Scott D. Solomon
ResearchOpen Access15 Dec 2022
Nature Medicine

Volume: 28, P: 2504-2511
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) is an anti-inflammatory drug proposed as a treatment for COVID19. Here the results are reported from a randomised trial testing DMF treatment in 713 patients hospitalised with COVID-19. DMF was not associated with any improvement in day 5 outcomes.

Peter Sandercock
Janet Darbyshire
Martin J. Landray
ResearchOpen Access31 Jan 2024
Nature Communications

Volume: 15, P: 1-13
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

A pre-specified meta-analysis of pooled, individual patient-level data from the DELIVER and DAPA-HF trials, testing dapagliflozin in patients with heart failure, demonstrates reductions in risk of cardiovascular-associated deaths and hospital admissions for heart failure, regardless of ejection fraction.

Pardeep S. Jhund
Toru Kondo
John J. V. McMurray
ResearchOpen Access27 Aug 2022
Nature Medicine

Volume: 28, P: 1956-1964
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Orly Vardeny
James C. Fang
Scott D. Solomon
Amendments and CorrectionsOpen Access17 Mar 2023
Nature Medicine

Volume: 29, P: 3269
Aspirin in primary prevention needs individual judgements

In May 2014, the FDA astutely stated that any decision to use aspirin should be an individual clinical judgement by health-care providers. Almost simultaneously, the MESA investigators formulated, but did not test, a hypothesis that coronary artery calcification scoring might aid health-care providers in making this judgement.

Charles H. Hennekens
David L. DeMets
News & Views24 Jun 2014
Nature Reviews Cardiology

Volume: 11, P: 438-440
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

R Hájek
T Masszi
H Ludwig
ResearchOpen Access24 Jun 2016
Leukemia

Volume: 31, P: 107-114
Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial

Andrew J Coldman
Lovedeep Gondara
Gina S Ogilvie
ResearchOpen Access17 Nov 2016
British Journal of Cancer

Volume: 115, P: 1487-1494

Search

Filter By:

Search

Quick links